These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Basis of HIV resistance suggests new vaccine strategy. Senior K Lancet; 2001 May; 357(9268):1594. PubMed ID: 11377653 [No Abstract] [Full Text] [Related]
3. What hope is there for an HIV vaccine? Witten G S Afr Med J; 2004 Oct; 94(10):831. PubMed ID: 15532757 [No Abstract] [Full Text] [Related]
4. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes. Yang OO AIDS; 2008 Jan; 22(3):325-31. PubMed ID: 18195558 [No Abstract] [Full Text] [Related]
5. No vaccine against HIV yet--are we not perfectly equipped? Singh M Virol J; 2006 Aug; 3():60. PubMed ID: 16939652 [TBL] [Abstract][Full Text] [Related]
6. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. Emini EA; Koff WC Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131 [No Abstract] [Full Text] [Related]
7. Measuring HIV-1-specific T cell immunity: how valid are current assays? D'Souza MP; Altfeld M J Infect Dis; 2008 Feb; 197(3):337-9. PubMed ID: 18184092 [No Abstract] [Full Text] [Related]
8. HIV vaccine efficacy trials: towards the future of HIV prevention. Kim D; Elizaga M; Duerr A Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236 [TBL] [Abstract][Full Text] [Related]
9. Progress toward an HIV vaccine. Letvin NL Annu Rev Med; 2005; 56():213-23. PubMed ID: 15660510 [TBL] [Abstract][Full Text] [Related]
11. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. McElrath MJ; Siliciano RF; Weinhold KJ AIDS Res Hum Retroviruses; 1997 Feb; 13(3):211-6. PubMed ID: 9115806 [No Abstract] [Full Text] [Related]
13. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576 [No Abstract] [Full Text] [Related]
14. Genetic and immune correlates of the HIV infection and vaccine-induced immunity. Foreword. Füst G Vaccine; 2008 Jun; 26(24):2949-50. PubMed ID: 18321613 [No Abstract] [Full Text] [Related]
15. HIV type 1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy. Ada GL; McElrath MJ AIDS Res Hum Retroviruses; 1997 Feb; 13(3):205-10. PubMed ID: 9115805 [No Abstract] [Full Text] [Related]
16. Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection. Gandhi RT; Walker BD Curr Opin Immunol; 2002 Aug; 14(4):487-94. PubMed ID: 12088684 [TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T-cell recognition of HIV proteins and peptides. Nixon DF; McMichael AJ AIDS; 1991 Sep; 5(9):1049-59. PubMed ID: 1718319 [No Abstract] [Full Text] [Related]
18. Development of prophylactic AIDS vaccines: the current state of affairs. Hanke T Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467 [TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. Angel JB; Routy JP; Tremblay C; Ayers D; Woods R; Singer J; Bernard N; Kovacs C; Smaill F; Gurunathan S; Sekaly RP AIDS; 2011 Mar; 25(6):731-9. PubMed ID: 21330911 [TBL] [Abstract][Full Text] [Related]
20. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]